vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). HCI Group, Inc. runs the higher net margin — 39.7% vs 35.5%, a 4.2% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs 18.4%). HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 9.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
ADMA vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $246.2M |
| Net Profit | $49.4M | $97.7M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 58.5% |
| Net Margin | 35.5% | 39.7% |
| Revenue YoY | 18.4% | 52.1% |
| Net Profit YoY | -55.9% | 3679.2% |
| EPS (diluted) | $0.20 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $246.2M | ||
| Q3 25 | $134.2M | $216.3M | ||
| Q2 25 | $122.0M | $221.9M | ||
| Q1 25 | $114.8M | $216.4M | ||
| Q4 24 | $117.5M | $161.9M | ||
| Q3 24 | $119.8M | $175.3M | ||
| Q2 24 | $107.2M | $206.2M | ||
| Q1 24 | $81.9M | $206.6M |
| Q4 25 | $49.4M | $97.7M | ||
| Q3 25 | $36.4M | $65.5M | ||
| Q2 25 | $34.2M | $66.2M | ||
| Q1 25 | $26.9M | $69.7M | ||
| Q4 24 | $111.9M | $2.6M | ||
| Q3 24 | $35.9M | $5.7M | ||
| Q2 24 | $32.1M | $54.1M | ||
| Q1 24 | $17.8M | $47.6M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 58.5% | ||
| Q3 25 | 38.0% | 41.9% | ||
| Q2 25 | 35.1% | 42.5% | ||
| Q1 25 | 30.4% | 46.4% | ||
| Q4 24 | 32.6% | 3.6% | ||
| Q3 24 | 33.1% | 8.0% | ||
| Q2 24 | 36.6% | 36.9% | ||
| Q1 24 | 26.7% | 37.5% |
| Q4 25 | 35.5% | 39.7% | ||
| Q3 25 | 27.1% | 30.3% | ||
| Q2 25 | 28.1% | 29.8% | ||
| Q1 25 | 23.4% | 32.2% | ||
| Q4 24 | 95.2% | 1.6% | ||
| Q3 24 | 30.0% | 3.2% | ||
| Q2 24 | 29.9% | 26.2% | ||
| Q1 24 | 21.7% | 23.0% |
| Q4 25 | $0.20 | $7.29 | ||
| Q3 25 | $0.15 | $4.90 | ||
| Q2 25 | $0.14 | $5.18 | ||
| Q1 25 | $0.11 | $5.35 | ||
| Q4 24 | $0.45 | $0.32 | ||
| Q3 24 | $0.15 | $0.52 | ||
| Q2 24 | $0.13 | $4.24 | ||
| Q1 24 | $0.08 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $1.2B |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.0B |
| Total Assets | $624.2M | $2.5B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $1.2B | ||
| Q3 25 | $61.4M | $987.9M | ||
| Q2 25 | $90.3M | $947.2M | ||
| Q1 25 | $71.6M | $754.5M | ||
| Q4 24 | $103.1M | $532.5M | ||
| Q3 24 | $86.7M | $518.8M | ||
| Q2 24 | $88.2M | $445.8M | ||
| Q1 24 | $45.3M | $655.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $1.0B | ||
| Q3 25 | $431.2M | $821.8M | ||
| Q2 25 | $398.3M | $758.6M | ||
| Q1 25 | $373.4M | $522.7M | ||
| Q4 24 | $349.0M | $453.3M | ||
| Q3 24 | $231.9M | $455.3M | ||
| Q2 24 | $188.3M | $447.3M | ||
| Q1 24 | $153.7M | $395.7M |
| Q4 25 | $624.2M | $2.5B | ||
| Q3 25 | $568.7M | $2.3B | ||
| Q2 25 | $558.4M | $2.4B | ||
| Q1 25 | $510.6M | $2.3B | ||
| Q4 24 | $488.7M | $2.2B | ||
| Q3 24 | $390.6M | $2.0B | ||
| Q2 24 | $376.4M | $1.9B | ||
| Q1 24 | $350.9M | $1.8B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $444.4M |
| Free Cash FlowOCF − Capex | $34.6M | $440.8M |
| FCF MarginFCF / Revenue | 24.8% | 179.0% |
| Capex IntensityCapex / Revenue | 0.8% | 1.5% |
| Cash ConversionOCF / Net Profit | 0.72× | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $444.4M | ||
| Q3 25 | $13.3M | $26.7M | ||
| Q2 25 | $21.1M | $145.0M | ||
| Q1 25 | $-19.7M | $162.0M | ||
| Q4 24 | $50.2M | $331.8M | ||
| Q3 24 | $25.0M | $104.1M | ||
| Q2 24 | $45.6M | $-29.0M | ||
| Q1 24 | $-2.2M | $182.0M |
| Q4 25 | $34.6M | $440.8M | ||
| Q3 25 | $-1.1M | $25.9M | ||
| Q2 25 | $18.7M | $144.5M | ||
| Q1 25 | $-24.4M | $160.3M | ||
| Q4 24 | $47.5M | $327.8M | ||
| Q3 24 | $24.0M | $103.2M | ||
| Q2 24 | $43.6M | $-30.1M | ||
| Q1 24 | $-4.6M | $181.0M |
| Q4 25 | 24.8% | 179.0% | ||
| Q3 25 | -0.8% | 12.0% | ||
| Q2 25 | 15.3% | 65.1% | ||
| Q1 25 | -21.2% | 74.1% | ||
| Q4 24 | 40.4% | 202.5% | ||
| Q3 24 | 20.0% | 58.9% | ||
| Q2 24 | 40.7% | -14.6% | ||
| Q1 24 | -5.6% | 87.6% |
| Q4 25 | 0.8% | 1.5% | ||
| Q3 25 | 10.7% | 0.4% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 2.5% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.5% | ||
| Q1 24 | 2.9% | 0.5% |
| Q4 25 | 0.72× | 4.55× | ||
| Q3 25 | 0.36× | 0.41× | ||
| Q2 25 | 0.62× | 2.19× | ||
| Q1 25 | -0.73× | 2.32× | ||
| Q4 24 | 0.45× | 128.41× | ||
| Q3 24 | 0.70× | 18.33× | ||
| Q2 24 | 1.42× | -0.54× | ||
| Q1 24 | -0.12× | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
